Researchers have developed a new laboratory method to test how well experimental cancer-fighting drugs can block an enzyme called SHMT that cancer cells need to survive. According to Gram Research analysis, this study tested nine different inhibitor compounds and found that the new testing approach successfully measured both how tightly drugs bind to the enzyme and whether they actually stop it from working. This is early-stage laboratory research that may eventually lead to new cancer treatments, but human testing is years away.
Scientists have developed a better way to test drugs that block an important enzyme called SHMT, which helps cancer cells grow. This enzyme is involved in making the building blocks cancer cells need to divide and multiply. Researchers tested nine different experimental drugs to see how well they could stop this enzyme from working. According to Gram Research analysis, this study provides the first comprehensive comparison of these newer cancer-fighting compounds using lab tests, which could help scientists develop better cancer treatments in the future.
Key Statistics
A 2026 laboratory study published in RSC Advances tested nine different SHMT inhibitor compounds to evaluate their effectiveness at blocking enzymes that cancer cells depend on for growth and division.
Researchers demonstrated that a new coupled enzyme testing method could reliably measure both the binding strength and functional activity of SHMT inhibitors, providing scientists with a standardized way to evaluate cancer-fighting drug candidates.
The study found that how tightly a drug binds to the SHMT enzyme doesn’t always perfectly predict how well it actually stops the enzyme from working, indicating that both measurements are necessary for proper drug evaluation.
The Quick Take
- What they studied: How well different experimental drugs can block an enzyme (SHMT) that cancer cells depend on to grow and divide
- Who participated: This was a laboratory study using purified enzyme proteins, not human subjects or patients
- Key finding: Researchers successfully tested nine different inhibitor compounds and identified which ones most effectively blocked SHMT1 and SHMT2 enzymes using a new testing method
- What it means for you: This research is an early-stage laboratory discovery that may eventually lead to new cancer treatments, but it’s not yet ready for human use. It helps scientists understand which experimental drugs show the most promise for further development
The Research Details
This was a laboratory-based biochemical study where researchers created pure versions of two enzymes called SHMT1 and SHMT2 in test tubes. They then tested nine different experimental drugs to see how well each one could stick to and block these enzymes. The researchers used two main testing methods: one that measures how tightly drugs bind to the enzyme (like testing how well a key fits in a lock), and another that measures whether the drugs actually stop the enzyme from working (like testing whether the key actually turns the lock). This approach allowed them to understand both how strongly the drugs attach to the enzyme and whether that attachment actually prevents the enzyme from doing its job.
Previous research identified several promising new cancer-fighting drugs that work differently than older treatments, but scientists didn’t have good ways to test how well these drugs actually worked. This study fills that gap by providing reliable laboratory methods to compare different drugs side-by-side. Having standardized testing methods is important because it helps scientists identify the most promising candidates to move forward into more expensive and time-consuming human studies.
This is a solid laboratory methods paper that provides detailed biochemical analysis. The researchers used well-established scientific techniques and created their own pure enzyme proteins to ensure consistency. The main limitation is that this is test-tube science—it doesn’t tell us whether these drugs would work in actual cancer patients or even in living cells. Laboratory results often don’t translate directly to real-world effectiveness.
What the Results Show
The researchers successfully tested nine different SHMT inhibitor compounds and compared how well each one blocked the two versions of the SHMT enzyme (SHMT1 and SHMT2). The study identified that some drugs worked much better than others at stopping the enzyme from functioning. The compounds tested included SHIN1, SHIN2, AGF347, W478, and five additional experimental drugs. By using their new testing method, the researchers could measure both how tightly each drug bound to the enzyme and how effectively it prevented the enzyme from doing its job—two different but related measurements. This comprehensive comparison provides the first detailed side-by-side analysis of these newer cancer-fighting compounds.
The study also demonstrated that their new testing approach—a coupled enzyme assay—could be reliably used to measure how well different SHMT inhibitors work. This methodological contribution is important because it gives other scientists a standardized way to test new drugs in development. The research showed that the binding strength (how tightly a drug sticks to the enzyme) doesn’t always perfectly predict how well the drug actually stops the enzyme from working, suggesting that both measurements are important for evaluating drug candidates.
Previous studies had identified these SHMT inhibitors as potentially useful cancer-fighting drugs, but comprehensive laboratory testing data was missing. This study fills that gap by providing the first detailed biochemical analysis of multiple inhibitors using consistent testing methods. The new testing approach builds on existing laboratory techniques but applies them in a way that hadn’t been done before for SHMT inhibitors, making it easier for future researchers to evaluate new drug candidates.
This research was conducted entirely in test tubes using purified enzymes, not in living cells or animals. Laboratory results often don’t translate to real-world effectiveness—drugs that work well in test tubes sometimes fail when tested in actual cancer cells or patients. The study doesn’t tell us whether these drugs would be safe or effective in humans, or whether they could reach cancer cells in the body. Additionally, the sample size of enzyme preparations and specific experimental conditions weren’t detailed in the abstract, so readers can’t fully assess all aspects of the methodology.
The Bottom Line
This is early-stage laboratory research that should not influence current cancer treatment decisions. It provides useful information for scientists developing new cancer drugs but is not yet applicable to patient care. Confidence level: This is foundational research that may eventually contribute to new treatments, but many steps remain before clinical use.
Cancer researchers and pharmaceutical scientists developing new treatments should care about this work. Patients with cancer should not expect these experimental drugs to be available soon—this is basic research, not a clinical breakthrough. People interested in how cancer drugs are developed will find this interesting as an example of early-stage drug discovery.
This is very early-stage research. If any of these compounds eventually become cancer treatments, it would likely take 5-10+ years of additional laboratory testing, animal studies, and human clinical trials before they could be used to treat patients.
Frequently Asked Questions
What is SHMT and why do cancer cells need it?
SHMT is an enzyme that helps cells make building blocks needed for DNA and cell division. Cancer cells use this enzyme to grow and multiply rapidly, making it a promising target for cancer drugs that could stop tumor growth.
Are these experimental drugs available to cancer patients now?
No. This is early-stage laboratory research testing how well drugs work in test tubes. Years of additional testing in cells, animals, and humans would be needed before any of these compounds could be used to treat patients.
How is this research different from previous SHMT studies?
This is the first comprehensive laboratory comparison of nine different SHMT inhibitors using standardized testing methods. Previous studies identified these drugs but lacked detailed biochemical data comparing their effectiveness side-by-side.
Could this lead to better cancer treatments?
Potentially. By identifying which experimental drugs most effectively block SHMT, researchers can focus development efforts on the most promising candidates, which may eventually lead to new cancer therapies if they prove safe and effective in human testing.
Why test drugs in test tubes instead of directly in patients?
Laboratory testing is faster, cheaper, and safer than human trials. It helps scientists eliminate ineffective drugs early and identify the most promising candidates before investing in expensive and time-consuming human studies.
Want to Apply This Research?
- Users interested in cancer research developments could track ‘SHMT inhibitor research milestones’ by noting when new studies on these compounds are published or when any advance to human testing
- While this research doesn’t suggest immediate lifestyle changes, users could use the app to track their interest in emerging cancer research and set reminders to check for updates on these experimental treatments as they progress through development
- Set up a quarterly check-in to review new publications on SHMT inhibitors and other emerging cancer therapies, tracking which compounds are advancing toward clinical trials
This research describes early-stage laboratory testing of experimental compounds and does not represent approved cancer treatments. These drugs are not available for human use and should not be considered as treatment options. Anyone with cancer should consult with their oncologist about proven, FDA-approved treatment options. This article is for educational purposes only and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.